BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Merck & Co., Inc. (MRK) Gets US Vaccine-Panel Backing For Cervical Cancer Shot


6/29/2006 12:40:10 PM

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--June 29, 2006--Merck & Co., Inc. announced today that the U.S. Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices (ACIP) voted unanimously to recommend that girls and women 11 to 26 years old be vaccinated with GARDASILĀ® (Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine) to prevent cervical cancer, precancerous and low-grade lesions, and genital warts caused by human papillomavirus (HPV) types 6, 11, 16 and 18. The Committee recommended that GARDASIL be administered to 11- and 12- year-old females and to females aged 13 to 26 who have not previously been vaccinated, and that nine- and 10-year-old females can be vaccinated with GARDASIL at the discretion of their physicians. The ACIP stated that Pap and HPV screening prior to vaccination are not necessary. The ACIP also recommended that females can receive GARDASIL regardless of whether they have or previously had an abnormal Pap test, a positive HPV test or genital warts.



Read at AP
Read at Bloomberg
Read at Reuters
Read at BioSpace.com

AP
Bloomberg
Reuters
BioSpace.com
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES